Gao Yu-Meng, Xu Bo-Wen, Liu Ping, Wang Yu-Li, Zhang Qing-You, Liao Ying, Du Jun-Bao, Jin Hong-Fang
Department of Pediatrics, Children's Medical Center, Peking University First Hospital, No. 8, Xi-Shi Ku Street, West District, Beijing, 100034, China.
Department of Cardiology, Beijing Children's Hospital, Capital Medial University, Beijing, 100045, China.
World J Pediatr. 2025 Apr 24. doi: 10.1007/s12519-025-00898-3.
Oral rehydration solution (ORS) is predominantly utilized in the management of hypovolemic postural orthostatic tachycardia syndrome (POTS). This study aimed to identify effective indicators and develop models to assess the impact of ORS on pediatric patients diagnosed with POTS.
We utilized a retrospective analysis of totally 158 pediatric patients with POTS receiving a 3-month course of ORS treatment. All patients were classified into training set (n = 98) and validation set (n = 60). Within the training set, univariate analysis and binary logistic regression were employed to select candidate predictors. To predict the efficacy of ORS in pediatric patients with POTS, a nomogram model and a scoring model were constructed and demonstrated. Additionally, the predictive ability and calibration performance were evaluated using receiver operating characteristic (ROC) curves, Hosmer-Lemeshow (H-L) goodness of fit test, and calibration plots. Decision curve analysis (DCA) was employed to assess the clinical applicability of the predictive models.
Body mass index (BMI) z-score, serum chlorine, and urine specific gravity (USG) before treatment were identified as significant and independent predictors of efficacy of ORS in pediatric patients with POTS. Consequently, these indicators were included in the predictive models. A nomogram model was constructed in the training set (AUC = 0.87, which yields a sensitivity of 84.5% and a specificity of 85.0%) and validated in the validation set (the sensitivity, specificity, and accuracy were 87.5%, 85%, and 86.7%, respectively). A scoring model was advanced in the training set (AUC = 0.88, which yields a sensitivity of 79.3% and a specificity of 82.5%) and validated in the validation set (the sensitivity, specificity, and accuracy were 77.5%, 80.0%, and 78.3%, respectively). The H-L test results indicated a good model fit. The calibration plots and DCA for both models exhibited excellent calibration and satisfactory net benefit.
Based on pre-treatment BMI z-score, serum chlorine, and USG, a nomogram model and a scoring model were developed and validated. The models can effectively assess the efficacy of ORS in pediatric patients with POTS, offering an accurate and individualized therapeutic strategy.
口服补液盐(ORS)主要用于治疗低血容量性体位性直立性心动过速综合征(POTS)。本研究旨在确定有效指标并建立模型,以评估ORS对诊断为POTS的儿科患者的影响。
我们对158例接受为期3个月ORS治疗的POTS儿科患者进行了回顾性分析。所有患者被分为训练集(n = 98)和验证集(n = 60)。在训练集中,采用单因素分析和二元逻辑回归来选择候选预测因子。为了预测ORS对POTS儿科患者的疗效,构建并展示了列线图模型和评分模型。此外,使用受试者工作特征(ROC)曲线、Hosmer-Lemeshow(H-L)拟合优度检验和校准图来评估预测能力和校准性能。采用决策曲线分析(DCA)来评估预测模型的临床适用性。
治疗前的体重指数(BMI)z评分、血清氯和尿比重(USG)被确定为ORS对POTS儿科患者疗效的显著且独立的预测因子。因此,这些指标被纳入预测模型。在训练集中构建了列线图模型(AUC = 0.87,灵敏度为84.5%,特异度为85.0%),并在验证集中进行了验证(灵敏度、特异度和准确度分别为87.5%、85%和86.7%)。在训练集中提出了评分模型(AUC = 0.88,灵敏度为79.3%,特异度为82.5%),并在验证集中进行了验证(灵敏度、特异度和准确度分别为77.5%、80.0%和78.3%)。H-L检验结果表明模型拟合良好。两个模型的校准图和DCA均显示出良好的校准和令人满意的净效益。
基于治疗前的BMI z评分、血清氯和USG,开发并验证了列线图模型和评分模型。这些模型可以有效地评估ORS对POTS儿科患者的疗效,提供准确且个性化的治疗策略。